NCT05909657 is a clinical trial of questionnaires (surveys) in Sickle Cell Disease, sponsored by The University of The West Indies.

Who is sponsoring NCT05909657?

NCT05909657 is sponsored by The University of The West Indies.

What drugs are being tested in NCT05909657?

Interventions in NCT05909657: questionnaires (surveys).

What condition does NCT05909657 study?

NCT05909657 studies Sickle Cell Disease.

Is NCT05909657 still recruiting?

NCT05909657 is currently status unknown. Last updated 6 July 2023.

Last reviewed 2023-07-06 · How we verify

NCT05909657

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enablers and Barriers to Hydroxyurea Use for Sickle Cell Disease Jamaica

Status unknown Last updated 6 July 2023

What this trial tests

trial testing questionnaires (surveys) in Sickle Cell Disease in 450 participants. Status unknown.

Timeline

1 July 2023

Primary endpoint
30 April 2024

31 December 2024

Quick facts

Lead sponsor	The University of The West Indies
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	450
Start date	1 July 2023
Primary completion	30 April 2024
Estimated completion	31 December 2024
Sites	1 location across Jamaica

Drugs / interventions tested

questionnaires (surveys)

Conditions studied

Sickle Cell Disease — all drugs for Sickle Cell Disease →

Sponsor

The University of The West Indies

Who can join

18 and older, any sex, with Sickle Cell Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sickle cell disease (SCD) is associated with a lifetime of medical and socio-behavioural complications that require coordination of care from multidisciplinary teams. Access to adequate care for SCD is important as inadequate access can contribute to increased acute care utilization, disjointed care delivery, and earlier mortality for many SCD patients. Hydroxyurea (HU) is the first drug approved for the treatment of SCD and improves many adverse outcomes of SCD and yet its use remains sub-optimal. This mixed-methods study aims to identify the barriers and enablers that SCD patients, caregivers of children (under age 18 years), and health care providers (including physicians, nurses and pharmacists) identify for health care access and HU utilization. The findings may guide development and implementation of strategies to improve access to SCD healthcare and HU uptake which may result in significant benefits to patients, families and the healthcare system including possible reduction in healthcare utilization. Participants will be recruited from the Sickle Cell Unit, Kingston and from all four Jamaican regional health authorities. Questionnaires and interview guides for provider and patient/caregiver assessments are adapted, with permission, from the Sickle Cell Disease Implementation Consortium tools. The study will also examine data on HU usage from the National Health Fund of Jamaica since its addition of SCD to its list of chronic illnesses in 2015. All data collected will be de-identified and maintained in a secure database, with access limited to key personnel. There is minimal risk to participants. Participants will be selected only because of the specific problem under investigation, and not because of easy availability, diminished autonomy, or social bias.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Sickle Cell Disease

Currently open trials in the same condition.

NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting

Other The University of The West Indies trials

Trials by the same sponsor.

NCT07177001 — Neck and Low Back Pain in Physical Therapy Students at The University of the West Indies, Mona, Jamaica · NA · not yet recruiting
NCT07167888 — Low Back and Neck Pain in Nursing Students at The University of The West Indies · NA · not yet recruiting
NCT07194746 — The Prevalence of Neck and Low Back Pain in FMSTRC Staff At the UWI Mona · NA · not yet recruiting
NCT05856968 — Investigation of Continuous Versus Interrupted Subcutaneous Fat Closure in Reducing Surgical Site Infection · NA · not yet recruiting
NCT05730244 — A Study of the Clinical Efficacy and Safety of 20% Cassia Alata Extract Against Tinea Versicolor · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05909657 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of The West Indies
Last refreshed: 6 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05909657.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing